Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
USNA Usana Health Sciences Inc
- Stocks
- Consumer Defensive
- NYSE: USNA
Price (delayed)
$30.02
Market cap
$559.06M
P/E Ratio
16.4
Dividend/share
N/A
EPS
$1.83
Enterprise value
$402.45M
USANA prides itself in providing consumers the highest quality nutritional products in the world. From its award-winning supplements to its innovative skincare line, USANA has proven for more than 25
Highlights
USNA's revenue is down by 2.7% year-on-year but it is up by 2.5% since the previous quarter
USNA's net income is down by 44% year-on-year and by 17% since the previous quarter
The EPS has contracted by 43% YoY and by 17% from the previous quarter
Key stats
What are the main financial stats of USNA
Market
Valuations
Earnings
Shares outstanding
18.62M
Market cap
$559.06M
Enterprise value
$402.45M
Price to earnings (P/E)
16.4
Price to book (P/B)
1.07
Price to sales (P/S)
0.65
EV/EBIT
6.03
EV/EBITDA
4.28
EV/Sales
0.46
Revenue
$876.24M
Gross profit
$705.65M
Operating income
$57.32M
Net income
$34.9M
EBIT
$66.7M
EBITDA
$94.09M
Free cash flow
$49.18M
Per share
Balance sheet
Liquidity
EPS
$1.83
EPS diluted
$1.82
Free cash flow per share
$2.58
Book value per share
$28.02
Revenue per share
$46
TBVPS
$23.9
Total assets
$746.6M
Total liabilities
$162.72M
Debt
$23M
Equity
$529.76M
Working capital
$144.01M
Debt to equity
0.04
Current ratio
2.05
Quick ratio
1.31
Net debt/EBITDA
-1.66
Margins
Efficiency
Dividend
EBITDA margin
10.7%
Gross margin
80.5%
Net margin
4%
Operating margin
6.5%
Return on assets
5%
Return on equity
6.6%
Return on invested capital
43.7%
Return on capital employed
10.9%
Return on sales
7.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
USNA stock price
How has the Usana Health Sciences stock price performed over time
Intraday
1.76%
1 week
3.77%
1 month
21.34%
1 year
-35.73%
YTD
-16.36%
QTD
11.31%
Financial performance
How have Usana Health Sciences's revenue and profit performed over time
Revenue
$876.24M
Gross profit
$705.65M
Operating income
$57.32M
Net income
$34.9M
Gross margin
80.5%
Net margin
4%
USNA's net income is down by 44% year-on-year and by 17% since the previous quarter
USNA's net margin is down by 42% YoY and by 18% from the previous quarter
The operating income has declined by 37% year-on-year and by 14% since the previous quarter
Usana Health Sciences's operating margin has decreased by 36% YoY and by 17% QoQ
Price vs fundamentals
How does USNA's price correlate with its fundamentals
Growth
What is Usana Health Sciences's growth rate over time
Valuation
What is Usana Health Sciences stock price valuation
P/E
16.4
P/B
1.07
P/S
0.65
EV/EBIT
6.03
EV/EBITDA
4.28
EV/Sales
0.46
The EPS has contracted by 43% YoY and by 17% from the previous quarter
The price to earnings (P/E) is 9% higher than the last 4 quarters average of 15.1 and 5% higher than the 5-year quarterly average of 15.6
USNA's P/B is 64% below its 5-year quarterly average of 3.0 and 18% below its last 4 quarters average of 1.3
USNA's price to sales (P/S) is 46% less than its 5-year quarterly average of 1.2 and 19% less than its last 4 quarters average of 0.8
USNA's revenue is down by 2.7% year-on-year but it is up by 2.5% since the previous quarter
Efficiency
How efficient is Usana Health Sciences business performance
Usana Health Sciences's ROA has decreased by 47% YoY and by 17% from the previous quarter
The ROE has contracted by 46% YoY and by 18% from the previous quarter
The company's return on invested capital fell by 39% YoY and by 14% QoQ
The ROS has contracted by 33% YoY and by 16% from the previous quarter
Dividends
What is USNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for USNA.
Financial health
How did Usana Health Sciences financials performed over time
The current ratio has increased by 2.5% from the previous quarter and by 2.5% YoY
USNA's debt is 96% less than its equity
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.